Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours (TROPION-PanTumor02)
Carcinoma, Non-Small-Cell Lung
Datopotamab Deruxtecan (Dato-DXd)
18 Years - 130 Years
Endpoint Classification: -
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Verified 01 Oct 2023 by AstraZeneca
Daiichi Sankyo, Inc.
No locations available
|Experimental: Dato-DXd Arm|
This single-arm study consists of multiple cohorts, divided by indication.